Brokerages Anticipate RXi Pharmaceuticals Corp (RXII) to Post -$0.56 Earnings Per Share

Brokerages forecast that RXi Pharmaceuticals Corp (NASDAQ:RXII) will post earnings of ($0.56) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for RXi Pharmaceuticals’ earnings. RXi Pharmaceuticals reported earnings of ($1.10) per share during the same quarter last year, which suggests a positive year over year growth rate of 49.1%. The business is expected to report its next quarterly earnings report on Thursday, August 9th.

According to Zacks, analysts expect that RXi Pharmaceuticals will report full year earnings of ($2.50) per share for the current fiscal year. For the next fiscal year, analysts forecast that the firm will post earnings of ($1.75) per share. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow RXi Pharmaceuticals.

RXi Pharmaceuticals (NASDAQ:RXII) last posted its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.90) earnings per share for the quarter. The company had revenue of $0.02 million for the quarter.

Separately, ValuEngine raised shares of RXi Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, April 2nd.

Shares of RXi Pharmaceuticals opened at $2.33 on Thursday, according to Marketbeat Ratings. RXi Pharmaceuticals has a twelve month low of $1.90 and a twelve month high of $7.70. The stock has a market capitalization of $10.55 million, a price-to-earnings ratio of -0.55 and a beta of 1.15.

RXi Pharmaceuticals Company Profile

RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.

Get a free copy of the Zacks research report on RXi Pharmaceuticals (RXII)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply